CN112703190A - Hdac6选择性抑制剂的晶型及其应用 - Google Patents

Hdac6选择性抑制剂的晶型及其应用 Download PDF

Info

Publication number
CN112703190A
CN112703190A CN201980044805.7A CN201980044805A CN112703190A CN 112703190 A CN112703190 A CN 112703190A CN 201980044805 A CN201980044805 A CN 201980044805A CN 112703190 A CN112703190 A CN 112703190A
Authority
CN
China
Prior art keywords
degrees
compound
formula
crystalline form
following
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980044805.7A
Other languages
English (en)
Other versions
CN112703190B (zh
Inventor
郭强
韦昌青
肖瑶
樊莉莉
钱文远
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KEYSTONE
CStone Pharmaceuticals Shanghai Co Ltd
CStone Pharmaceuticals Suzhou Co Ltd
Original Assignee
KEYSTONE
CStone Pharmaceuticals Shanghai Co Ltd
CStone Pharmaceuticals Suzhou Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KEYSTONE, CStone Pharmaceuticals Shanghai Co Ltd, CStone Pharmaceuticals Suzhou Co Ltd filed Critical KEYSTONE
Publication of CN112703190A publication Critical patent/CN112703190A/zh
Application granted granted Critical
Publication of CN112703190B publication Critical patent/CN112703190B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

本发明公开了式(Ⅰ)所示化合物的A晶型，及其在制备治疗HDAC6相关疾病的药物的应用。

Description

PCT国内申请，说明书已公开。

Claims (9)

  1. PCT国内申请，权利要求书已公开。
CN201980044805.7A 2018-07-04 2019-07-03 Hdac6选择性抑制剂的晶型及其应用 Active CN112703190B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810726102 2018-07-04
CN201810726102X 2018-07-04
PCT/CN2019/094602 WO2020007329A1 (zh) 2018-07-04 2019-07-03 Hdac6选择性抑制剂的晶型及其应用

Publications (2)

Publication Number Publication Date
CN112703190A true CN112703190A (zh) 2021-04-23
CN112703190B CN112703190B (zh) 2022-08-05

Family

ID=69059255

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980044805.7A Active CN112703190B (zh) 2018-07-04 2019-07-03 Hdac6选择性抑制剂的晶型及其应用

Country Status (6)

Country Link
US (1) US11345682B2 (zh)
EP (1) EP3822267B1 (zh)
JP (1) JP7348214B2 (zh)
CN (1) CN112703190B (zh)
ES (1) ES2961765T3 (zh)
WO (1) WO2020007329A1 (zh)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103429574A (zh) * 2010-11-16 2013-12-04 阿塞蒂隆制药公司 作为蛋白质去乙酰化酶抑制剂的嘧啶羟基酰胺化合物和其使用方法
WO2015007870A1 (en) * 2013-07-18 2015-01-22 Institut De Recherche Pour Le Developpement (I.R.D.) New compounds for the treatment and/or prevention of parasitic diseases and method of production of thereof
WO2015100363A1 (en) * 2013-12-23 2015-07-02 The Trustees Of Columbia University In The City Of New York Selective hdac6 inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
SG11201906361YA (en) * 2017-01-10 2019-08-27 Cstone Pharmaceuticals Suzhou Co Ltd Hdac6 selective inhibitors, preparation method therefor, and application thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103429574A (zh) * 2010-11-16 2013-12-04 阿塞蒂隆制药公司 作为蛋白质去乙酰化酶抑制剂的嘧啶羟基酰胺化合物和其使用方法
WO2015007870A1 (en) * 2013-07-18 2015-01-22 Institut De Recherche Pour Le Developpement (I.R.D.) New compounds for the treatment and/or prevention of parasitic diseases and method of production of thereof
WO2015100363A1 (en) * 2013-12-23 2015-07-02 The Trustees Of Columbia University In The City Of New York Selective hdac6 inhibitors

Also Published As

Publication number Publication date
JP7348214B2 (ja) 2023-09-20
EP3822267A1 (en) 2021-05-19
EP3822267B1 (en) 2023-08-30
WO2020007329A1 (zh) 2020-01-09
JP2021529767A (ja) 2021-11-04
ES2961765T3 (es) 2024-03-13
EP3822267A4 (en) 2022-03-30
US20210147394A1 (en) 2021-05-20
US11345682B2 (en) 2022-05-31
CN112703190B (zh) 2022-08-05

Similar Documents

Publication Publication Date Title
EP3070089B1 (en) Aminomethyl tryptanthrin derivative, preparation method and application thereof
JP5479105B2 (ja) 新規ユビキリン結合性小分子
JP2016535788A5 (zh)
UA121161C2 (uk) Кристалічна форма a агоніста tlr7, її спосіб одержання і використання
WO2016086824A1 (zh) 一种Bouchardatine和Bouchardatine衍生物及其制备方法和应用
WO2022174525A1 (zh) 一类化合物及其制备方法和用途
WO2015165352A1 (zh) 一类新型的kcnq钾通道激动剂、其制备方法和用途
CN109096235B (zh) 2,2-二甲基苯并吡喃类衍生物及其制备方法和用途
CN112703190B (zh) Hdac6选择性抑制剂的晶型及其应用
TW201922690A (zh) 環－amp反應元素結合蛋白的抑制劑
WO2019091046A1 (zh) 一种来那度胺的衍生物的制备方法与应用
CN112679409B (zh) 一种4-吲哚-取代硫半脲衍生物及其制备方法和应用
CN113214097B (zh) 治疗阿尔茨海默病的化合物
CN114736202A (zh) 具有ido1/tdo抑制活性的小檗碱衍生物的制备及用途
CN110172058B (zh) 7-氮杂螺[5.6]十二烷-10-酮类化合物及其制备方法与用途
JP2022507558A (ja) チエノピリドン誘導体のカリウム塩一水和物及びその調製方法
CN113831346B (zh) 多靶点抗肿瘤小分子及其衍生物、制法、药物组合物和应用
CN106608824B (zh) 芳酸酯类化合物及其制备方法和用途
JPWO2004020433A1 (ja) 新規結晶
JP3740284B2 (ja) 抗マラリア活性を有する新規化合物又はその塩
CN106432244B (zh) 一种hedgehog信号通路抑制剂的结晶形式及其制备方法
JP5641054B2 (ja) 新規化合物、並びに、キネシンスピンドルタンパク質阻害剤及びその応用
EP4043436A1 (en) Magl inhibitor, preparation method therefor and use thereof
CN116284018A (zh) 一种呋喃并[2,3-b]喹啉衍生物的制备方法及其应用
CN116715610A (zh) 一种新型sting小分子抑制剂及其制备方法与应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant